News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference

December 12, 2017

PledPharma AB
Company Announcement

Principal investigator James Dear presents Aladote as a potential new treatment
for late stage liver toxicity after paracetamol overdose at Pharmacology
conference

PledPharma announces that an abstract presenting preclinical data for
calmangafodipir has been accepted and will be presented at the British
Pharmacological Society's annual Pharmacology conference in London during
December 11-13, 2017. 

Stockholm, 2017-12-12 12:00 CET (GLOBE NEWSWIRE) -- 

The work was a collaboration between Dr. James Dear and his group at the
University of Edinburgh and PledPharma. The abstract, “Mouse and human
translational drug development of calmangafodipir as a new treatment for
paracetamol overdose”, has received acceptance for an oral presentation of
results from the preclinical study and the design of the ongoing Aladote
clinical study at the British Pharmacological Society's flagship annual meeting
taking place at the Queen Elizabeth II Conference Centre in London on the 11 –
13 December 2017. The presentation will cover preclinical data indicating
calmangafodipir could be used as an effective treatment for paracetamol
poisoning in patients who present late to hospital when standard of care
antidote (acetylcysteine, NAC) has lost efficacy. 

Based on the preclinical data, a proof of principle study with the focus on
safety and tolerability in patients attending hospital following a paracetamol
overdose has started at the Edinburgh Royal Infirmary and the first patient was
included in June. 

“The fact that the Abstract has been selected for oral presentation at the
Pharmacology meeting underlines the interesting pre-clinical data for
calmangafodipir as a potential new treatment modality for paracetamol
(acetaminophen) overdose patients and illustrates the growing interest in
treating this patient group.” says Nicklas Westerholm, CEO PledPharma 

Abstract Number: OC013;

Abstract Title: Mouse and human translational drug development of
calmangafodipir as a new treatment for paracetamol overdose. 

Date: Tuesday, December 12, 2017, 3:45 PM. Oral Communications: Clinical
Pharmacology II. 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Nicklas.westerholm@pledpharma.se



About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see http://www.pledpharma.se/

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com